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Coronary Microvascular Function and Cardiovascular Risk Factors in
Women With Angina Pectoris and No Obstructive Coronary Artery
Disease: The iPOWER Study
Naja Dam Mygind, MD;* Marie Mide Michelsen, MD;* Adam Pena, MD; Daria Frestad, MD; Nynne Dose, BSc; Ahmed Aziz, MD;
Rebekka Faber, MD; Nis Høst, MD, PhD; Ida Gustafsson, MD, PhD; Peter Riis Hansen, MD, DMSc; Henrik Steen Hansen, MD, DMSc;
C. Noel Bairey Merz, MD; Jens Kastrup, MD, DMSc; Eva Prescott, MD, DMSc
Background-—The majority of women with angina-like chest pain have no obstructive coronary artery disease when evaluated with
coronary angiography. Coronary microvascular dysfunction is a possible explanation and associated with a poor prognosis. This
study evaluated the prevalence of coronary microvascular dysfunction and the association with symptoms, cardiovascular risk
factors, psychosocial factors, and results from diagnostic stress testing.
Methods and Results-—After screening 3568 women, 963 women with angina-like chest pain and a diagnostic coronary
angiogram without signiﬁcant coronary artery stenosis (<50%) were consecutively included. Mean age (SD) was 62.1 (9.7).
Assessment included demographic and clinical data, blood samples, questionnaires, and transthoracic echocardiography during
rest and high-dose dipyridamole (0.84 mg/kg) with measurement of coronary ﬂow velocity reserve (CFVR) by Doppler examination
of the left anterior descending coronary artery. CFVR was successfully measured in 919 (95%) women. Median (IQR) CFVR was
2.33 (1.98–2.76), and 241 (26%) had markedly impaired CFVR (<2). In multivariable regression analysis, predictors of impaired
CFVR were age (P<0.01), hypertension (P=0.02), current smoking (P<0.01), elevated heart rate (P<0.01), and low high-density
lipoprotein cholesterol (P=0.02), but these variables explained only a little of the CFVR variation (r2=0.09). CFVR was not
associated with chest pain characteristics or results from diagnostic stress testing.
Conclusion-—Impaired CFVR was detected in a substantial proportion, which suggests that coronary microvascular dysfunction
plays a role in the development of angina pectoris. CFVR was associated with few cardiovascular risk factors, suggesting that CFVR
is an independent parameter in the risk evaluation of these women. Symptom characteristics and results from stress testing did
not identify individuals with impaired CFVR. ( J Am Heart Assoc. 2016;5:e003064 doi: 10.1161/JAHA.115.003064)
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M ore than half of women with angina-like chest painreferred for clinical coronary angiography (CAG) have
no obstructive coronary artery disease (CAD), and this is twice
as often seen in women compared with men after the CAG.1
While previously considered a benign condition, recent
studies have found the condition to be associated with
persistent chest pain, repeated angiograms, reduced quality
of life, and increased cardiovascular morbidity and mortality.1–
3 A possible explanation for the discrepancy between
symptoms and CAG ﬁndings could be ischemia caused by
coronary microvascular dysfunction (CMD). Recent studies
have convincingly demonstrated that CMD is a strong
predictor of cardiovascular prognosis,4–6 and CMD is common
in both men and women with no obstructive CAD.4
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Previous studies of CMD among subjects with angina with
no obstructive CAD have been based on relatively small,
selected populations and little is known about the burden of
CMD. CMD can be assessed as reduced coronary ﬂow velocity
reserve (CFVR) invasively during the CAG,5 by positron emission
tomography7,8 or by transthoracic Doppler echocardiography
(TTDE) of the left anterior descending coronary artery (LAD)
during dipyridamole or adenosine infusion. With perhaps as
little as 5% of patients with angina needing revascularization, as
found in the PROspective Multicenter Imaging Study for
Evaluation of Chest Pain (PROMISE) trial,9 the need for
assessment of CMD is expanding and it is important to also
evaluate CMD outside of the few dedicated centers that
routinely perform invasive assessment of CMD during the CAG.
Although there is an increasing interest in CMD, several gaps in
knowledge remain. Thus, little is known about the burden of
CMD among women with angina and no obstructive CAD and
the correlation with symptoms, results of stress tests, and risk
factors, since this has never been systematically assessed in an
unselected population. Also, knowledge regarding the prog-
nostic implications of CMD and effective treatment targeting
both symptoms and prognosis are needed.
The iPOWER study (ImProve diagnOsis and treatment of
Women with angina pEctoris and micRovessel disease) aims
to investigate diagnostic possibilities and prognosis of
impaired CFVR in women with angina-like chest pain and no
obstructive CAD.10 We investigated CMD prevalence mea-
sured with TTDE-assessed CFVR and the association with
cardiovascular risk factors in women with angina who were
consecutively sampled after diagnostic invasive CAG. Further,
we examined whether CMD was associated with character-
istics, severity, and frequency of angina-like chest pain and
results of diagnostic stress testing.
Methods
Population
Participants were recruited from the database PATS (Patient
Analysis & Tracking System; Dendrite Clinical Systems), which
covers eastern Denmark with 3 million inhabitants. All
women (18–80 years) referred between March 2012 and
September 2014 for a clinically indicated diagnostic CAG due
to angina-like chest pain and suspected obstructive CAD were
screened according to previously described well-deﬁned
inclusion and exclusion criteria (Figure 1).10 We included
both women referred for stable angina and women hospital-
ized suspected of unstable angina, since the latter may be
ﬁrst manifestation of stable angina. Women with elevated
cardiac markers or ST-segment elevation were excluded
(Figure 1). All women were included within 1 year of their
CAG.
Basic Examination
Basic assessment included clinical and demographic data.
Trained health professionals interviewed participants regard-
ing cardiac symptoms with respect to location, character,
duration, radiation, frequency, and provoking and alleviating
factors. According to the classical classiﬁcation of chest pain
symptoms were classiﬁed as typical angina pectoris, atypical
angina pectoris and non-cardiac chest pain.11,12 Question-
naires regarding chest pain symptoms included the Seattle
Angina Questionnaire, which evaluates 5 dimensions of
functional status,13 and the World Health Organization’s
Rose’s Angina Questionnaire, which evaluates symptoms as
deﬁnite angina or not, further subdividing those with deﬁnite
angina as severe or nonsevere.14
We obtained information regarding cardiovascular risk
factors (age, body mass index [BMI], diabetes, hypertension,
hyperlipidemia, smoking, family history of cardiovascular
disease, and menopausal status), comorbidity, previous
hospital admissions, and previous diagnostic tests, which
included noninvasive cardiac computed tomography–angiog-
raphy (CTA), exercise electrocardiography (ECG), and single-
photon emission computed tomography (SPECT) performed
within 6 months before CAG from interviews and charts.
ECG, blood pressure, and heart rate measures were
obtained at rest, and abdominal circumference was mea-
Figure 1. Inclusion and exclusion criteria in the iPOWER study.
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sured. The ECG was analyzed for signs of ischemia (inverted
T wave, pathological Q wave, ST-segment depression),
bundle-branch block, and atrial ﬁbrillation. Blood samples
were analyzed for cholesterol levels (total, low-density
lipoprotein [LDL], and high-density lipoprotein [HDL]
cholesterol), triglycerides, creatinine level, and glycated
hemoglobin (HbA1c). A spot urine sample was analyzed for
microalbuminuria.
Echocardiographic Examination
All participants underwent standard transthorarcic echocar-
diography and TTDE of the LAD during rest and high-dose
dipyridamole stress (0.84 mg/kg) over 6 minutes to obtain
coronary ﬂow velocities (CFVs) at baseline and at maximal
hyperemia. Different vasodilators can be used to induce
hyperemia, but the majority of TTDE studies of CFVR have
used dipyridamole. Adenosine and dipyridamole are regarded
as equal to achieve peak coronary vasodilation15,16 and are
used interchangeably in clinical practice. Echocardiographic
examinations were performed by using the GE Healthcare
Vivid E9 cardiovascular ultrasound system (GE Healthcare)
with a 1.3- to 4.0-MHz transducer (GE Vivid 5S probe) for
standard echocardiography and a 2.7- to 8-MHz transducer
(GE Vivid 6S probe) for TTDE. Images were stored for ofﬂine
analysis (GE EchoPac v.112). The same 4 experienced
echocardiographers performed all examinations in the same
settings. Before examination, participants were instructed to
be abstinent from caffeine or food containing signiﬁcant
amount of methylexanthine (coffee, tea, chocolate, cola, and
banana) for 24 hours. Medication containing dipyridamole was
paused for 48 hours; long-lasting nitroglycerin, b-blockers,
angiotensin-converting enzyme inhibitors, angiotensin type II
antagonists, calcium antagonists, and diuretics were paused
for 24 hours; and short-lasting nitroglycerin was paused for
1 hour before the examination. Participants were studied in
the left lateral decubitus position. The octave was set at 3.1/
6.2 MHz, frequency at 8 MHz for B-mode (2D), while a
baseline color scale between 1.00–2.50 kHz (velocity range
10–24 cm/s) was chosen according to low or high ﬂow
velocities respectively. Color gain was adjusted to provide
optimal 2-dimensional imaging quality. LAD was visualized
with color Doppler in an apical modiﬁed foreshortened 2- or 4
chamber view or in a modiﬁed short-axis view of the left
ventricle. CFV was measured with pulsed-wave Doppler as a
laminar ﬂow toward the transducer. We aimed to align the
ultrasound beam direction to the LAD ﬂow by adjusting probe
position during recording of 2-dimensional and pulse-wave
images. In case of difﬁculty in visualization of the LAD, a
microbubble contrast agent was used (SonoVue; Bracco
Imaging). Acquisitions of CFV during dipyridamole infusion
were obtained throughout the infusion or up to 3 minutes after
the infusion had terminated until ﬂow had reached peak
velocity. Blood pressure and heart rate were measured every
3 minutes during the examination of CFVR. After the exam-
ination, intravenous theophylline (maximum dose 220 mg)
was administered to relieve potential side effects of dipyri-
damole.
For the analysis of CFVR, diastolic peak ﬂow velocities
were measured at rest and at peak hyperemia (Figure 2).
CFVR was calculated as the ratio between peak velocities
during stress and during rest. Two experts, blinded to
participant data, analyzed every CFVR examination indepen-
dently. The ﬁrst reading was used, except for estimates that
differed by >0.2, in which case the 2 analyzers reanalyzed the
CFVR examination and reached agreement. In our previous
validation study with repeated TTDE CFVR examinations in 10
young, healthy subjects by the same observer, we found an
intraclass correlation coefﬁcient of 0.97 (95% CI 0.92–1.00)
and coefﬁcient of variation of 7% (95% CI 3–10%) for repeat
examinations. In a subsample of 50 participants from the
iPOWER study, CFVR readings for the 2 observers were highly
reproducible.10
Left ventricular ejection fraction (LVEF) was analyzed by a
skilled echocardiographer as an automated biplane calculation
(Auto-EF tool; GE EchoPac v.112).
Statistical Analyses
Continuous variables with a Gaussian distribution are
expressed as meanSD (standard deviation) values.
MedianIQR (interquartile range) values are used for
variables with a non-Gaussian distribution. Count in percent
Figure 2. Measurement of coronary ﬂow velocity. DPV indicates
diastolic peak velocity.
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values is used for categorical variables. Distribution was
assessed graphically. Difference between participants and
nonparticipants was tested by using 1-way ANOVA or v2
test for continuous and categorical variables, respectively.
Missing values in the Seattle Angina Questionnaire were
imputed according to the validated scoring system.13
Participants were divided into 3 groups according to
CFVR, based on current guidelines for determination of
CMD by using a cutoff point of 2.017 and a previously used
cutoff point of 2.5.18 Age-adjusted trend tests by multivari-
able adjusted logistic or linear regression analysis were
used to evaluate the distribution of variables (cardiovascular
risk factors, clinical assessment, laboratory tests, results
from diagnostic stress testing, medical history including
medication, and psychosocial factors) among the 3 CFVR
groups. Dependent variables with skewed distribution
(smoking duration and menopause duration) were logarith-
mically transformed to base 2. Symptom characteristics
from questionnaires were evaluated by using age-adjusted
trend tests or v2 if parameters of interest were divided into
3 categories. Moreover, to explore whether each symptom
variable was a predictor of reduced CFVR, age-adjusted
linear regression analyses were performed with natural
logarithmically transformed CFVR as outcome variable
because of non-Gaussian distribution. Interaction analysis
was performed to investigate possible differences in
association between participants regarded as having stable
or unstable angina at the time of the CAG.
To explore predictors of reduced CFVR, multivariable
linear regression analyses were performed with natural
logarithmically transformed CFVR. All potential explanatory
variables with an a priori deﬁned hypothesis (age, hyper-
tension, smoking status, diabetes, BMI, cholesterol, post-
menopausal status, systolic blood pressure, resting heart
rate, nonobstructive atherosclerosis at CAG, HDL, non-high-
density lipoprotein cholesterol (non-HDL), and triglycerides)
were tested in a prioritized order as determinants of CFVR
and discarded at a cutoff level of P≥0.10. Assumptions of
linearity, variance homogeneity, and Gaussian distribution of
residuals were assessed graphically. The logarithmically
transformed parameter estimates in the regression
equation were converted back to the original scale for
interpretation as an expected percentage change in
CFVR value for each parameter by using the equation:
1(eparameterestimate)9100%. Interaction analysis was per-
formed to investigate difference in association between
participants with stable or unstable angina. A likelihood
ratio test was used to test difference between the ﬁnal
model and a model including interactions.
Conﬁdence interval (CI) refer to 95% intervals, and a 2-
sided P value <0.05 was considered signiﬁcant. All analyses
were performed by using STATA/IC 13.1 (StataCorp LP).
Ethics
This study was performed in accordance with the Helsinki
Declaration and was approved by the Danish Regional
Committee on Biomedical Research Ethics (H-3-2012-005).
All participants have given written informed consent on oral
and written information.
Results
Study Population
Of the 5288 women with angina undergoing CAG in eastern
Denmark between March 2012 and September 2014, 2159
were eligible for the study, 963 were included, and 919 had
successfully measured CFVR (Figure 3). Of the included
participants, 72% were categorized as having stable angina
and 28% as having unstable angina at the time of CAG.
Median interval (IQR) between diagnostic clinical CAG and
CFVR examination was 71 days (51–97 days). A microbubble
contrast agent (SonoVue; Bracco Imaging) was used in 59
(6%) participants. Almost all participants experienced side
effects during the CFVR examination (98%), and on a visual
analog scale from 1 to 10, the mean (SD) severity of
symptoms reported by the participants was 5.7 (2.6). Two
participants had an inherent atrial ﬁbrillation induced by
dipyridamole, and one experienced a delayed universal
urticarial reaction. A higher proportion of nonparticipants
had hypertension, diabetes mellitus, or nonobstructive
atherosclerosis at CAG and stable angina pectoris as CAG
indication, and more were currently smoking compared with
participants (Table 1). This was similar when including only
participants referred with stable angina.
Characteristics of Participants With CMD
Median (IQR) CFVR was 2.33 (1.98–2.76) and did not differ
between participants with stable angina and those with
unstable angina (P=0.89). A total of 241 (26%) participants
had a CFVR ≤2, 318 (35%) had a CFVR between 2 and 2.5, and
360 (39%) had a CFVR >2.5. Table 2 displays characteristics
of the study population by CFVR level. Participants with lower
CFVR were signiﬁcantly older. After age adjustment, partic-
ipants with impaired CFVR had signiﬁcantly more history of
hypertension, diabetes mellitus, current smoking, elevated
heart rate and more nonobstructive atherosclerosis at CAG.
Participants with low CFVR also had signiﬁcantly lower HDL
cholesterol levels (P=0.02) whereas CFVR was not associated
with other serum lipid measures. Low CFVR was associated
with a higher use of acetylsalicylic acid (P=0.02), which was
partly explained by a higher proportion with nonobstructive
CAD. CFVR was not associated with cardiovascular medica-
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tion such as b-blockers, calcium antagonists, angiotensin-
converting enzyme inhibitors, or statins (Table 2), and there
was no relation between CFVR and comorbidities such as
musculoskeletal, pulmonary, thyroid, gastrointestinal, or
gynecologic disease. There was no signiﬁcant association
between CFVR and results from a resting 12-lead study ECG
(signs of ischemia, bundle-branch block, or atrial ﬁbrillation).
However, only 25 (3%) participants had atrial ﬁbrillation. LVEF
was not associated with impaired CFVR, but participants with
LVEF <45% were excluded.
Baseline CFV correlated with CFVR (r=0.42, P<0.001),
but CFV was not associated with the same cardiovascular risk
Table 1. Background Characteristics on Included Participants and Nonparticipants
Participants (n=963) Nonparticipants (n=1196) P Value
Age, y, mean (SD) 62.1 (9.7) 62.7 (10.8) 0.19
Body mass index, kg/m2, mean (SD) 27.3 (5.4) 27.4 (6.0) 0.71
Hypertension, n (%) 487 (51) 598 (59) 0.001
Hyperlipidemia, n (%) 604 (63) 672 (66) 0.16
Diabetes mellitus, n (%) 127 (13) 177 (17) 0.02
Family history of CAD, n (%) 496 (53) 501 (51) 0.34
Smoking (current), n (%) 152 (16) 231 (22) <0.001
Stable angina pectoris, n (%) 693 (72) 918 (77) 0.01
Atherosclerosis at CAG, n (%) 335 (35) 513 (43) <0.001
Resident outside the capital region, n (%) 293 (30) 366 (31) 0.93
P value from 1-way ANOVA or v2 test. CAD indicates coronary artery disease; CAG, coronary angiography.
Figure 3. Participant ﬂow chart. CAD indicates coronary artery disease; CAG, coronary angiography;
CFVR, coronary ﬂow reserve.
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factors as was CFVR. CFV was like CFVR associated with
smoking (P=0.004) and heart rate (P<0.001). Cardiovascular
risk factor associations with CFVR were similar for partici-
pants characterized as having stable (n=693) versus unstable
angina (all P values for interaction >0.05).
Determinants of CFVR
In multivariable regression analyses, CFVR remained associ-
ated with age, hypertension, smoking, resting heart rate, and
HDL cholesterol in the ﬁnal model (Table 3). However, the
model explained only a minor part of the variation in CFVR
(r2=0.09). Adjusting for baseline CFV, which was strongly
associated with CFVR, did not alter associations (results not
shown). There was no signiﬁcant interaction effect of stable
versus unstable angina on the associations between cardio-
vascular risk factors and CFVR and no signiﬁcant difference
between our ﬁnal model and a model including full interaction
analysis (P=0.54).
When looking at smoking amount as a determinant of
CFVR, adjusting only for age, CFVR decreased 4.6% (95% CI
2.0–7.2%) per 10 pack-year ([20 cigarettes/d]10 y) for
Table 2. Participant Characteristics According to Coronary Flow Velocity Reserve Level
CFVR≤2.0 (n=241) 2<CFVR≤2.5 (n=318) CFVR>2.5 (n=360) P Value
Age, y, mean (SD) 65.0 (9.2) 62.0 (9.7) 60.0 (9.5) <0.001
Stable angina pectoris, n (%) 64 (27) 91 (29) 107 (30) 0.89
Hypertension, n (%) 143 (59) 168 (53) 156 (44) 0.02
Hyperlipidemia, n (%) 161 (67) 205 (65) 214 (60) 0.51
Diabetes mellitus, n (%) 40 (17) 42 (13) 35 (10) 0.02
Family history of CAD, n (%) 117 (49) 170 (55) 190 (54) 0.64
Smoking (current), n (%) 46 (19) 57 (18) 46 (13) 0.001
Pack-years, [20 cigarettes/d]y,† median (IQR) 20 (2–35) 15 (2–30) 10 (0–20) <0.001
Peripheral or cerebral vascular disease, n (%) 28 (12) 38 (12) 35 (10) 0.84
Atherosclerosis at CAG, n (%) 100 (41) 116 (36) 100 (28) 0.05
Postmenopausal status, n (%) 134 (85) 150 (74) 159 (68) 0.38
Menopause duration, y,‡ median (IQR) 18 (10–23) 15 (8–21) 13.5 (7–20) 0.65
Clinical assessment, mean (SD)
Body mass index, kg/m2 27.4 (5.8) 27.3 (5.4) 26.9 (5.1) 0.11
Abdominal circumference, cm 98 (14) 98 (15) 97 (14) 0.27
Systolic blood pressure, mm Hg 134 (22) 133 (21) 133 (22) 0.37
Heart rate at rest, bpm 71 (12) 71 (11) 69 (11) 0.001
LVEF, % 59 (6) 59 (6) 58 (6) 0.19
Medication, n (%)
Acetylsalicylic acid 123 (51) 150 (48) 134 (38) 0.02
b-Blockers 82 (35) 101 (32) 88 (25) 0.12
Calcium antagonists 57 (24) 68 (22) 73 (21) 0.69
Angiotensin-converting enzyme inhibitor 35 (15) 61 (20) 40 (11) 0.36
Statins 139 (58) 155 (50) 164 (46) 0.11
Angiotensin type II receptor blockers 59 (25) 51 (16) 56 (16) 0.08
Pantoprazole 48 (20) 65 (20) 62 (17) 0.67
Previous diagnostic stress tests, n (%)
Positive exercise testk (n=317) 22 (28) 37 (33) 40 (32) 0.52
Positive SPECTk (n=99) 11 (33) 12 (36) 8 (24) 0.41
P value from age-adjusted trend test (multivariable regression and logistic regression). CAD indicates coronary artery disease; CAG, coronary angiography; LVEF, left ventricular ejection
fraction.
†Only including previous and current smokers.
‡Only postmenopausal participants with natural menopause.
kOnly participants with stable angina pectoris who had a diagnostic stress test before CAG.
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current smokers and 2.4% (95% CI 0.8–4.0%) per 10 pack-year
([20 cigarettes/d]10 y) for previous smokers.
Symptoms
Of the participants, 471 (53%) had symptoms weekly and 306
(32%) had typical angina symptoms according to the classic
characterization of chest pain.11,12 There was no association
between CFVR level and symptom burden or symptom
characteristics according to the classic classiﬁcation of chest
pain11,12 and Rose’s Angina Questionnaire. In addition, there
was no association between CFVR level and angina frequency,
angina stability, and treatment satisfaction evaluated by using
the Seattle Angina Questionnaire, but participants with low
CFVR had a signiﬁcantly higher degree of physical limitation
and a higher self-perception of disease as assessed by using
the Seattle Angina Questionnaire (Figure 4). There was no
association between impaired CFVR and whether angina
pectoris occurred during rest, exertion, rest and exertion, or
dipyridamole infusion. Further, we found no difference in
number of hospital admissions or contacts with general
practitioner (Table 4).
Among participants referred for stable angina, 317 (47%)
had previously undergone an exercise ECG and 101 (15%) had
undergone SPECT. A positive stress test (exercise ECG or
SPECT) could not identify participants with CMD assessed by
using TTDE (Table 2).
Discussion
In this large study in which we systematically investigated the
association between symptoms, cardiovascular risk factors,
and noninvasively assessed CMD in women with angina-like
chest pain and no obstructive CAD, we found that CFVR was
impaired in a large proportion and was associated with age,
hypertension, current smoking, elevated resting heart rate,
and low HDL cholesterol. No convincing correlation between
severity or characterization of chest pain and impaired CFVR
was found, and a positive diagnostic stress test did not
identify participants with CMD.
The burden of symptoms was similar to that of previous
studies of obstructive CAD. Prevalence of typical angina in our
population was identical to that of women with obstructive
CAD from the CONFIRM registry (coronary CT angiography
evaluation for clinical outcomes: an international multicenter
registry).19 In our study, 50% of all participants had angina-like
chest pain at least once a week. For comparison, in the
clinical outcomes utilizing revascularization and aggressive
drug evaluation (COURAGE) study of subjects with obstructive
CAD, 40% had angina at least once a month at 3-year follow-
up.20 Participants in the COURAGE study also scored higher
on all 5 elements in the Seattle Angina Questionnaire
compared with the participants in the current study, indicating
better function.20 Another study found that participants with
nonobstructive atherosclerosis at CAG have more persistent
angina compared with participants with obstructive CAD
evaluated by using the Seattle Angina Questionnaire.3
Together, the ﬁndings indicate an overall limited association
between symptoms and angiographic CAD severity. We
further found that degree of CFVR impairment was not
associated with symptom characteristics and that the classic
characterization of chest pain could not be used to identify
CMD.11 The results may question whether CMD is the cause
of symptoms in these women. However, we have only
Figure 4. Seattle Angina Questionnaire. Higher scores represent
higher/better function of each variable in Seattle Angina Ques-
tionnaire. *P value from trend-test (age-corrected multivariate
regression). ‡P value from regression analysis with natural
logarithmically transformed CFVR as outcome. CFVR indicates
coronary ﬂow velocity reserve.
Table 3. Final Multivariable Regression Model in 885 Women
Expected
Change of
CFVR Value* 95% CI P Value
Age (for 10 y of aging) 6.2 8.0 to 4.4 <0.001
Hypertension 4.0 7.2 to 0.8 0.016
Smoking
Previous 1.9 5.2 to +1.6 0.29
Current 8.6 12.7 to 4.0 <0.001
Heart rate (for increase
of 10 bpm)
2.3 3.8 to 0.8 0.002
High-density
lipoprotein (per 1-
mmol/L increase)
+4.1 +0.8 to +7.2 0.016
P value obtained by multivariable linear regression analyses with ln base logarithmic
transformed coronary ﬂow velocity reserve (CFVR) as outcome variable.
*Percent increase (indicated by +) or decrease (indicated by ) in percent per unit
increase of independent variables.
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assessed 1 dimension of CMD. In this present study, we have
not assessed the endothelium-dependent epicardial dysfunc-
tion or mechanisms pertaining to pain perception, epicardial
disease, or noncardiac causes of chest pain such as gastric
pain, musculoskeletal disorders, or pulmonary disease. This
might as well explain the lack of association between angina
pectoris and CFVR. Studies simultaneously targeting symp-
toms and CMD are needed to clarify this.
We found that 26% of the women had CFVR <2 and, thus,
CMD according to current guidelines.17 This is in agreement
with several other studies. In a previous study of TTDE-assessed
CFVR in 394 participants (48%men) with angina pectoris and no
angiographic stenosis, 22% of participants had CMD, and
further, CMD was associated with a hazard ratio of 16 for death
or nonfatal myocardial infarction.6 Another study in 65 women
with angina and no obstructive CAD found a TTDE-measured
CFVR <2 in 40%.21 Other studies assessing CMD invasively or
by positron emission tomography with different cutoffs have
indicated that 39% to 54% have CMD.4,5,22 In a recent large
study with invasive assessment of CMD in 1439 men and
womenwith chest pain and nonobstructive CAD included over a
period of 19 years, 30% had abnormal CFVR in response to
adenosine.23
In the present study, the prevalence of risk factors and the
use of medication were similar to results from another large
Danish study of 2253 women with angina pectoris and no
obstructive CAD.1 Prevalence of risk factors was also
comparable to the National Heart, Lung, and Blood Institute
Women’s Ischemia Syndrome Evaluation (WISE) study of
women with chest pain and no signs of obstructive CAD.
However, our population was 8 years older and fewer were
current smokers.24 Overall, the prevalence of cardiovascular
risk factors was relatively high compared with that of a
general Danish population of women at a similar age.25
Table 4. Classiﬁcation of Chest Pain Variables According to CFVR Level
CFVR≤2.0 (n=241) 2<CFVR≤2.5 (n=318) CFVR>2.5 (n=360) P Value* P Value†
Symptom characteristics for classic chest pain classification, n (%)
Typical AP 71 (30) 102 (32) 122 (34) 0.17 0.96
Atypical AP 129 (54) 150 (47) 156 (43)
Noncardiac chest pain 41 (17) 66 (21) 82 (23)
Rose’s angina classification, n (%)
Severe definite AP 45 (19) 56 (18) 61 (17) 0.91 0.49
Nonsevere definite AP 56 (24) 73 (24) 94 (27)
Nondefinite AP 130 (56) 174 (57) 195 (56)
Symptom burden by Seattle Angina Questionnaire, mean (SD)
Physical limitation 71 (22) 73 (24) 77 (22) 0.02‡ 0.003
Angina stability 63 (29) 62 (29) 65 (28) 0.17 0.05
Angina frequency 76 (23) 74 (24) 77 (22) 0.33 0.25
Treatment satisfaction 67 (25) 65 (24) 67 (24) 0.42 0.56
Perception/quality of life 48 (29) 50 (26 51 (25) 0.04‡ 0.03
Further chest pain classification, n (%)
Chest pain at exertion 41 (19) 50 (18) 51 (17) 0.88 0.79
Chest pain at rest 67 (32) 92 (33) 106 (36)
Chest pain at exertion and rest 104 (49) 137 (49) 139 (47)
Chest pain during dipyridamole infusion 70 (31) 112 (36) 119 (35) 0.91 0.76
Reproduced symptoms during dipyridamole infusion 68 (30) 96 (32) 95 (28) 0.22 0.11
Weekly chest discomfort 120 (53) 164 (56) 173 (51) 0.30 0.24
Contact with health care system, mean (SD)
Previous hospitalization as a result of AP 1 (1) 1 (2) 1 (1) 0.60 0.84
Previous contacts with general practitioner as a result of AP 3 (4) 3 (4) 3 (3) 0.33 0.14
In some categories, there are missing data. AP indicates angina pectoris.
*P value from age-adjusted trend test (logistic or regression analyses) or chi-square test when symptom parameters of interest are divided into 3 categories.
†P value from age-adjusted linear regression analysis with natural logarithmically transformed coronary ﬂow velocity reserve (CFVR) as outcome.
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Reduced CFVR was associated with some, but not all,
traditional cardiovascular risk factors. This was compara-
ble to other studies that have found age,5,6,21,22,26,27
hypertension,6,27,28 diabetes mellitus,27,28 smoking status,26
resting heart rate,29 and HDL cholesterol26 to be determi-
nants of CFVR, including in multiple adjusted models. One
study in obese men and women with no obstructive CAD
found impaired CFVR to be related to a high BMI.29 In another
report, CFVR was associated with years since menopause and
the absence of hormone therapy postmenopause.22 We did
not ﬁnd relations between CFVR and BMI, menopause or lack
of hormonal therapy and CFVR in this large cohort and one
reason may be that none of the mentioned studies adjusted
for age, which is highly correlated to CFVR. However, the
explanatory effect of the variation of CFVR in our ﬁnal model
was low, indicating that although associations are present,
traditional cardiovascular risk factors account for little of the
variation in CFVR, which is in accordance with previously
published results from the National Heart, Lung, and Blood
Institute WISE study24 and another recent large study.23
It is often assumed that a positive stress test in the
presence of no obstructive CAD is indicative of microvascular
dysfunction. One study of 68 women found that signiﬁcantly
more women with low CFVR had a positive clinical stress
test.21 This could not be corroborated in our study: among the
47% of participants who had a stress test performed, a
positive stress test was not predictive of CMD. A recent large
study that included 1439 subjects with angina and invasive
assessment of CMD also found no association between
results of stress testing and CMD.23 The cause of the positive
stress tests is unclear; however, it is plausible that CMD can
cause ischemia without positive stress testing since these are
mostly based on demonstration of regional rather than diffuse
ischemia. Other cardiovascular indices might explain more of
the variation in CFVR than traditional cardiovascular risk
factors. Studies that include factors of vessel stiffness such
as brachial–ankle pulse-wave velocity, augmentation index,
and aortic pulse-wave velocity achieve a greater explanatory
effect of the CFVR variation with r2 values ranging from 0.36
to 0.52.30,31
A full invasive assessment including both endothelial and
nonendothelial mechanisms is regarded as the “gold stan-
dard” for assessing CMD. However, given that only a
minority of patients with angina will ultimately need
revascularization; noninvasive methods for assessment of
CMD deserve wider application. Recent evidence has shown
that CMD assessed by positron emission tomography among
patients with no visual evidence of CAD on rest/stress
positron emission tomography–myocardial perfusion imaging
was a powerful predictor of major cardiovascular events with
a hazard ratio of 0.8 per 10% increase in CFVR.4 Thus,
noninvasive assessment of CMD may prove an important
means of risk-stratifying this group. The present study
demonstrates that this is feasible in the vast majority of
unselected subjects and that the results are similar to those
found by using invasive assessment. In addition, TTDE
assessment of CMD is easily available given appropriate
training and can be repeatedly assessed with no concern of
radiation.
Strengths and Limitations
A main strength of this study is the systematic inclusion of
participants who represent women with clinically assessed
angina pectoris and no obstructive CAD in a region covering
almost 3.0 million inhabitants. All women referred to CAG for
angina were systematically screened and invited. Participants
represent both the capital and rural areas. Nonparticipants
had a greater burden of some cardiovascular risk factors and
more nonobstructive atherosclerosis at CAG compared with
participants, and this may have led us to underestimate the
prevalence of CMD. The most common reason not to
participate in the study was exhaustion and lack of energy,
and this could also explain why nonparticipants had more
cardiovascular risk factors. However, the internal validity is
not likely to be affected by nonparticipants. Prevalence of
CMD was comparable to previous studies, but more informa-
tion on whether CFVR differs between clinically determined
symptomatic and atypically symptomatic women or asymp-
tomatic women not referred could have been addressed by
including a matched control group of asymptomatic women.
Future studies will address this.
We have assessed 1 dimension of CMD; the adenosine-
induced reduced CFVR, which is mainly caused by dysfunction
of the endothelium-independent vasodilation of the microcir-
culation. We have not assessed the endothelium-dependent
epicardial dysfunction or microvascular spasm, which can be
detected by using invasive acetylcholine provocation test.32–
34 The latter might have been the main mechanism respon-
sible for chest pain in a subgroup of participants included in
this study, in particular those with unstable angina pectoris.
Therefore, the burden of CMD might be underestimated in this
study.
Conclusion
In the iPOWER study, CMD was systematically assessed by
TTDE with high feasibility. One-third of the women had
impaired CFVR and this was not associated with symptom
characteristics or severity, or with results from diagnostic
stress testing. CFVR was associated with only a few
traditional cardiovascular risk factors. Further follow-up will
determine whether assessment of CMD is useful to risk
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stratify the large population of women with angina and no
obstructive CAD and to monitor effects of intervention.
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